Finance

Lists
ARE:NYSE
Alexandria Real Estate Equities, Inc
USD 46,46
-1,91%
(-0,90) 1D
5 Okt., 14:07:11 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ARE...
Open
USD 46,99
High
USD 48,02
Low
USD 46,33
Mkt. cap
8,10 mjd
Avg. vol.
1,94 m
Volume
649,67 k
Dividend
6,20%
Quarterly dividend
USD 0,72
Ex-dividend date
30 Sep. 2026
52-wk high
USD 84,30
52-wk low
USD 39,41
EPS
-USD 6,06
Beta
1,16
Shares outstanding
174,25 m
No. of employees
514
Open
USD 46,99
High
USD 48,02
Low
USD 46,33
Mkt. cap
8,10 mjd
Avg. vol.
1,94 m
Volume
649,67 k
Dividend
6,20%
Quarterly dividend
USD 0,72
Ex-dividend date
30 Sep. 2026
52-wk high
USD 84,30
52-wk low
USD 39,41
EPS
-USD 6,06
Beta
1,16
Shares outstanding
174,25 m
No. of employees
514
News stories
From web sources and news partners
Profile
Alexandria Real Estate Equities, Inc. is a real estate investment trust based in Pasadena, California that invests in office buildings and laboratories leased to tenants in the life science and technology industries. Properties are generally located near universities to attract tenants. The company owns several major technology/biotechnology office campuses including the 740,972 square foot Alexandria Center for Life Science in Manhattan, and the 2,365,487 square foot Alexandria Center at Kendall Square and the 1,181,635 square foot Technology Square in the Boston area. The company is dependent on the life sciences industry and funding for research by the United States Government. The company also has a venture capital arm, Alexandria Venture Investments, which invests in life sciences firms. The company is named after Alexandria, Egypt because of that city's connection to science. Wikipedia
About Alexandria Real Estate Equities, Inc
CEOPeter M. Moglia
Employees514
Founded01 Jan. 1994
HeadquartersPasadena, Kalifornië, Verenigde State van Amerika
SectorReal estate investment trust
Websiteare.com
Analyst ratings
Based on 12 analysts giving stock ratings to ARE in the past 3 months
Hold
Buy
3
Hold
7
Sell
2
12-month forecast
Based on 12 Wall Street analysts offering 12 month price targets for ARE in the last 3 months.
Highest
Current USD 46,46
USD 60,00 (+29,13%)
Average
USD 53,64 (+15,44%)
Lowest
USD 48,00 (+3,30%)
Analyst
Recommendation
Action
Price target
Projected
Date
John Kim
BMO Capital
Hold
Reiterated
USD 48,00
+3,3%
09/29/2026
Anthony Paolone
J.P. Morgan
Sell
Downgraded
USD 56,00
+20,5%
09/24/2026
James Kammert
Evercore ISI
Buy
Maintained
USD 59,00
+27%
09/21/2026
Julien Blouin
Goldman Sachs
Hold
Maintained
USD 54,00
+16,2%
08/25/2026
Farrell Granath
Bank of America Securities
Hold
Maintained
USD 55,00
+18,4%
08/24/2026
Wes Golladay
Robert W. Baird
Hold
Maintained
USD 52,00
+11,9%
08/24/2026
Michael Carroll
RBC Capital
Hold
Maintained
USD 51,00
+9,8%
08/10/2026
Nicholas Joseph
Citi
Hold
Maintained
USD 50,00
+7,6%
08/10/2026
Richard Anderson
Cantor Fitzgerald
Hold
Reiterated
USD 52,00
+11,9%
08/04/2026
Ronald Kamdem
Morgan Stanley
Sell
Maintained
USD 53,00
+14,1%
08/04/2026
Michael Tupholme
TD Cowen
Buy
Reiterated
-
-
07/30/2026
Vikram Malhotra
Mizuho Securities
Buy
Maintained
USD 60,00
+29,1%
07/06/2026
Jeffrey Spector
Bank of America Securities
Hold
Maintained
USD 54,00
+16,2%
06/26/2026
Jonathan Petersen
Jefferies
Hold
Maintained
USD 57,00
+22,7%
01/30/2026
Last report
04 Aug. 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
USD 0,15 / USD 0,12
+26,17%beat
Revenue / Est. (USD)
663,20 m / 655,00 m
+1,25%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
752,14 m
754,11 m
670,88 m
663,20 m
Cost of goods sold
239,23 m
232,54 m
224,14 m
207,34 m
Cost of revenue
239,23 m
232,54 m
224,14 m
207,34 m
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
29,22 m
28,02 m
34,68 m
36,86 m
Operating expense
369,45 m
350,08 m
340,13 m
341,24 m
Total operating expenses
608,69 m
582,63 m
564,27 m
548,58 m
Operating income
143,46 m
171,48 m
106,61 m
114,62 m
Other non operating income
-
-
-
-
EBT including unusual items
-197,84 m
-995,35 m
398,38 m
-38,97 m
EBT excluding unusual items
116,77 m
105,81 m
37,44 m
183,50 m
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-232,75 m
-1,08 mjd
361,65 m
-72,78 m
Net profit margin
-30,95%
-143,33%
53,91%
-10,97%
Earnings per share
0,50
-
-
0,15
Interest and investment income
28,16 m
-
-
133,23 m
Interest expense
-54,85 m
-65,67 m
-69,17 m
-64,34 m
Net interest expenses
-26,69 m
-65,67 m
-69,17 m
68,88 m
Depreciation and amortization charges
340,23 m
322,06 m
305,44 m
304,38 m
EBITDA
477,23 m
487,66 m
406,43 m
410,62 m
Gain or loss from assets sale
-9,37 m
-619,91 m
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google-programme